Italia markets closed

Dow Jones
39.387,76
+331,37(+0,85%)
Nasdaq
16.346,26
+43,51(+0,27%)
Nikkei 225
38.073,98
-128,39(-0,34%)
EUR/USD
1,0784
+0,0032(+0,30%)
Bitcoin EUR
58.194,57
+1.190,12(+2,09%)
CMC Crypto 200
1.343,88
+43,78(+3,37%)

NVCR May 2024 15.000 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

1,2000

+0,1000

(+9,09%)

In data: 03:14PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in